Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC 4.0Drug Design, Development and Therapy

Atorvastatin for the Prevention of Cisplatin-Induced Ototoxicity: A Randomized Controlled Trial

6 affiliations
  1. 1Department of Pharmacy Practice, Faculty of Pharmacy, Minia University, Minia, Egypt
  2. 2ENT Department (Audio-Vestibular Medicine), Faculty of Medicine, Minia University, Minia, Egypt
  3. 3Department of Clinical Oncology, Faculty of Medicine, Minia University, Minia, Egypt
  4. 4Department of Clinical Oncology, Minia Oncology Institute, Minia, Egypt
  5. 5Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
  6. 6Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt

Abstract

Purpose: Cisplatin is used to treat a variety of tumors, it has a significant ototoxic effect; as studies show that about 40% to 70% of patients treated with cisplatin suffer hearing loss to some extent, which may lead to social isolation, anxiety, depression, and an overall negative effect on quality of life. Atorvastatin has a promising otoprotective potential based on preclinical and observational evidence, but the clinical evidence remains limited and not definitive. This is a randomized controlled trial aimed to investigate the efficacy of Atorvastatin co-administered during cisplatin chemotherapy against its ototoxicity in patients with solid tumors.

Patients and methods: This randomized controlled trial was conducted at the oncology center and the audio-vestibular unit, Minia university, Egypt, involving 56 patients with different solid tumors scheduled to receive cisplatin. Patients were randomized to receive either Atorvastatin 10 mg daily or no intervention. Baseline and final audiograms were obtained, the primary outcome is to measure change in pure-tone audiometric thresholds from baseline to post-treatment in both groups. The secondary outcome is to assess severity (grade) of hearing loss as well as the subjective hearing impairment in both groups using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) V.6 and the Speech, Spatial, and Qualities of Hearing Scale (SSQ) short version (SSQ12) questionnaire, respectively.

Results: A percentage of 41.38% of the case group and 44.4% of the control group experienced cisplatin-induced ototoxicity (CIO) according to NCI-CTCAE V.6 criteria. No significant difference was found between cases and controls regarding CIO measured by audiogram or data obtained from patients through the SSQ12 questionnaire.

Conclusion: Use of atorvastatin (10 mg daily) was not significantly associated with a reduction in CIO, as assessed by change in hearing thresholds, CTCAE criteria, or SSQ12 questionnaire.

Trial Registration: https://clinicaltrials.gov/study/NCT06553157.

Identifier: NCT06553157.

Related

  1. Capsaicin Modulates DNA Damage Related Gene Expressions in Cisplatin-Induced Ototoxicity.
    Yavuz Kerem Altun, Yüksel Olgun, Ayça Pamukoğlu Kaynar +2
    Laryngoscope investigative otolaryngologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Perioperative intravenous lidocaine for the prevention of chronic postsurgical pain: a systematic review and meta-analysis of randomized controlled trials
    Wei-Jing Zhu, Ran An, Qian-Yun Pang +1
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. The cooking for health optimization and disease prevention (CHOP) trial for improving cardiometabolic and mental health among older adults: study protocol for a randomized controlled trial
    Mia H. Putnam, Jin Dai, Difei Liu +6
    TrialsPeer-reviewedCC BY 4.0Clinical trials & evidence synthesisCrossref
  4. Comparative Efficacy of Vancomycin and Fidaxomicin Regimens for the Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
    C. Prosty, G. Butler-Laporte, J. Brophy +18
    medRxivPreprintAll rights reservedFull textInfectious diseasemedRxiv
  5. Double Versus Single Gloving in Gynecologic and Obstetric Procedures for the Prevention of Surgical Glove Perforation: A Meta-Analysis of Randomized Controlled Trials Doppeltes versus einfaches Handschuhtragen bei gynäkologischen und geburtshilflichen Eingriffen zur Prävention chirurgischer Handschuhperforationen: eine Metaanalyse randomisierter kontrollierter Studien
    Flora Jales Coan, Caroline Alencar De Nicola, Bárbara Schroeder Micchelucci +1
    Geburtshilfe und FrauenheilkundePeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCEurope PMCPMC
BibTeX
@article{helmy2026atorvastatin,
  title = {{Atorvastatin for the Prevention of Cisplatin-Induced Ototoxicity: A Randomized Controlled Trial}},
  author = {Noha H Helmy and Eman Mohamed Sadek and Dalia Fahim Mohammed Fahim and Nada Hussein Sholkamy and Sumaiah J Alarfaj and Fatma M Mady},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  month = nov,
  doi = {10.2147/dddt.s649303},
  url = {https://doi.org/10.2147/dddt.s649303},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Atorvastatin for the Prevention of Cisplatin-Induced Ototoxicity: A Randomized Controlled Trial
AU  - Noha H Helmy
AU  - Eman Mohamed Sadek
AU  - Dalia Fahim Mohammed Fahim
AU  - Nada Hussein Sholkamy
AU  - Sumaiah J Alarfaj
AU  - Fatma M Mady
PY  - 2026
DA  - 2026/11/07
JO  - Drug Design, Development and Therapy
DO  - 10.2147/dddt.s649303
UR  - https://doi.org/10.2147/dddt.s649303
AB  - Purpose: Cisplatin is used to treat a variety of tumors, it has a significant ototoxic effect; as studies show that about 40% to 70% of patients treated with cisplatin suffer hearing loss to some extent, which may lead to social isolation, anxiety, depression, and an overall negative effect on quality of life. Atorvastatin has a promising otoprotective potential based on preclinical and observational evidence, but the clinical evidence remains limited and not definitive. This is a randomized controlled trial aimed to investigate the efficacy of Atorvastatin co-administered during cisplatin chemotherapy against its ototoxicity in patients with solid tumors.  Patients and methods: This randomized controlled trial was conducted at the oncology center and the audio-vestibular unit, Minia university, Egypt, involving 56 patients with different solid tumors scheduled to receive cisplatin. Patients were randomized to receive either Atorvastatin 10 mg daily or no intervention. Baseline and final audiograms were obtained, the primary outcome is to measure change in pure-tone audiometric thresholds from baseline to post-treatment in both groups. The secondary outcome is to assess severity (grade) of hearing loss as well as the subjective hearing impairment in both groups using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) V.6 and the Speech, Spatial, and Qualities of Hearing Scale (SSQ) short version (SSQ12) questionnaire, respectively.  Results: A percentage of 41.38% of the case group and 44.4% of the control group experienced cisplatin-induced ototoxicity (CIO) according to NCI-CTCAE V.6 criteria. No significant difference was found between cases and controls regarding CIO measured by audiogram or data obtained from patients through the SSQ12 questionnaire.  Conclusion: Use of atorvastatin (10 mg daily) was not significantly associated with a reduction in CIO, as assessed by change in hearing thresholds, CTCAE criteria, or SSQ12 questionnaire.  Trial Registration: https://clinicaltrials.gov/study/NCT06553157.  Identifier: NCT06553157.
SN  - 1177-8881
ER  -